The Impact of the JOBS Act on IPOs for Life Sciences Companies

Share

Title I of the JOBS Act, which was signed into law in April of this year, represents a sea change in (1) the US initial public offering process and (2) the regulatory regime applicable to almost all newly public companies.

Mark Roeder, Global Co-chair of the Life Sciences Industry Group of Latham & Watkins, will moderate a panel with Joel Trotter, one of two lawyers who served on the IPO Task Force—the group whose recommendations gave rise to Title I of the JOBS Act — Scott Morrison, US Life Sciences Director for E&Y, and Brian Cuneo, an attorney in Latham & Watkins’ Life Sciences Group. The panelists will discuss the effect of the JOBS Act on life sciences companies considering a US IPO, their underwriters, sponsors and financial advisors. The panelists will also cover lessons learned during the first wave of IPOs under the JOBS Act and industry-specific trends that are emerging as a result of these dramatic changes to the IPO framework and the landscape for newly public companies.